Clinical Programs

Our purpose is to make
a difference for patients

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics is sponsoring several clinical trials  to deliver the power of T cells to cancer patients. The purpose of these trials is to develop innovative immunotherapies aimed at targeting a patient’s tumor selectively and effectively.

We have a big goal: overcome the challenges of fighting cancer and bring new therapeutic products to cancer patients. We do this with a singular passion and relentless focus to achieve better outcomes for patients.

Clinical
Trials

The following three clinical trials are currently open and recruiting patients:

The IMA201-101 trial (NCT03247309) is a first-in-human Phase 1 trial evaluating safety, tolerability and initial signs of clinical efficacy of Immatics’ ACTengine® product candidate, IMA201, which targets melanoma-associated antigen 4 or 8 (MAGEA4/A8) in patients with recurrent and/or refractory solid tumors.

Among the range of solid cancer indications, this study focuses on indications that include head and neck squamous cell carcinoma (HNSCC), squamous non-small cell carcinoma (squamous NSCLC), ovarian cancer, bladder cancer and subtypes of sarcoma due to the high prevalence of MAGEA4/8 expression in these tumors.

For more information on this clinical trial, click here

The IMA203-101 trial (NCT03686124) is a first-in-human Phase 1 trial evaluating the safety, tolerability, and initial signs of clinical efficacy of Immatics’ ACTengine® product candidate, IMA203, which targets preferentially expressed antigen in melanoma (PRAME), in patients with recurrent and/or refractory solid tumors.

Among a broad range of solid cancer indications, uterine cancer (endometrial cancer and uterine carcinoma), ovarian cancer, melanoma, several subtypes of sarcoma and squamous NSCLC are of special interest because the PRAME peptide is expressed in these tumors with a very high frequency.

Based on interim results from the Phase 1a study, Immatics is expanding the IMA203 study to three Phase 1b dose expansion cohorts, each designed to evaluate the observed objective response rate, demonstrate durability of response and provide the basis for entering registration trials. Cohorts include IMA203 as monotherapy in focus indications, IMA203 in combination with an immune checkpoint inhibitor and IMA203CD8, a 2nd generation monotherapy where IMA203 is co-transduced with a CD8 co-receptor, thereby inducing anti-tumor activity of both CD4 and CD8 T cells.

For more information on this clinical trial, click here

The IMA401-101 trial (NCT05359445) is a first-in-human Phase 1 trial evaluating safety, tolerability, and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors. TCER® IMA401 targets MAGEA4/8 and will be developed in collaboration with Bristol Myers Squibb.

The Phase 1 trial investigates IMA401 in patients with tumors of high MAGEA4/8 prevalence, such as squamous non-small cell lung carcinoma (sqNSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian carcinomas, as well as melanoma, sarcoma subtypes and other solid cancer types.

For more information on this clinical trial, click here

If you are a patient and interested participating in one of Immatics’ clinical trials, please speak to your treating physician.